FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

March 26,2021

Feb. 27, 2021

Abstract: Large Phase 3 clinical trials of the two FDA-authorized COVID-19 vaccines, mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech), have demonstrated efficacies of 94.1% (n = 30,420, 95% CI: 89.3-96.8) and 95% (n = 43,448, 95% CI: 90.3-97.6) in preventing symptomatic COVID-19, respectively. Given the ongoing vaccine rollout to healthcare personnel and residents of long-term care facilities, here we provide a preliminary assessment of real-world vaccination efficacy in 62,138 individuals from the Mayo Clinic and associated health system (Arizona, Florida, Minnesota, Wisconsin) between December 1st 2020 and February 8th 2021. Our retrospective analysis contrasts 31,069 individuals receiving at least one dose of either vaccine with 31,069 unvaccinated individuals who are propensity-matched based on demographics, location (zip code), and number of prior SARS-CoV-2 PCR tests. 8,041 individuals received two doses of a COVID-19 vaccine and were at risk for infection at least 36 days after their first dose. Administration of two COVID-19 vaccine doses was 88.7% effective in preventing SARS-CoV-2 infection (95% CI: 68.4-97.1%) with onset at least 36 days after the first dose. Furthermore, vaccinated patients who were subsequently diagnosed with COVID-19 had significantly lower 14-day hospital admission rates than propensity-matched unvaccinated COVID-19 patients (3.7% vs. 9.2%; Relative Risk: 0.4; p-value: 0.007). Building upon the previous randomized trials of these vaccines, this study demonstrates their real-world effectiveness in reducing the rates of SARS-CoV-2 infection and COVID-19 severity among individuals at highest risk for infection.

Authors:  Colin Pawlowski1+, Patrick Lenehan1+, Arjun Puranik1, Vineet Agarwal1, AJ Venkatakrishnan1, Michiel J.M. Niesen1, John C. O’Horo2, Abinash Virk2, Melanie D. Swift2, Andrew D. Badley2, John Halamka2, Venky Soundararajan1*,
1nference, Cambridge, MA 02142
2Mayo Clinic, Rochester, MN 55902
+Joint first authors
Correspondence: Venky Soundararajan (venky@nference.net)

Media coverage:



Screen Shot 2021-04-01 at 2.21.32 PM

Screen Shot 2021-03-29 at 10.20.34 AM

Screen Shot 2021-03-29 at 10.21.59 AM

Screen Shot 2021-03-29 at 10.23.41 AM

Screen Shot 2021-03-29 at 10.26.13 AM

Screen Shot 2021-03-30 at 5.44.40 PM

Screen Shot 2021-03-30 at 5.46.38 PM

Screen Shot 2021-04-01 at 8.43.39 AM


The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.